Want to track MYGN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
MYGN earnings report is expected in 6 days (3 Mar 2026)
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
Myriad Genetics Inc. NASDAQ: MYGN is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests including hereditary cancer tests that assess the risk for developing certain types of cancer based on genetics.
Marketbeat | 1 year ago
Myriad Genetics (MYGN) and GSK Unite to Boost HRD Testing
Myriad Genetics (MYGN) collaborates with GSK to improve access to HRD diagnostic testing for HGSOC patients.
Zacks | 1 year ago
Myriad Genetics (MYGN) Banks on Innovation Amid Macro Woes
Myriad Genetics (MYGN) continues to enhance its customer targeting, digital marketing and overall operating model to drive commercial leverage in 2024 and beyond.
Zacks | 1 year ago
